Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Recurrence 4Leukemia, Myeloid, Acute 3Leukemia 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rubinstein-Taybi Syndrome 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Carcinoma, Transitional Cell 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms × mocetinostat × Clear all
NCT00372437 2015-07-01

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Mirati Therapeutics Inc.

Phase 1/2 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

NCT00323934 2015-01-08

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Mirati Therapeutics Inc.

Phase 1 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡